Videos

Here are the top 5 biosimilar articles for the week of June 28, 2021.

Here are the top 5 biosimilar articles for the week of June 21, 2021.

Tahir Amin, Dip LP, co-executive director of I-MAK, discusses some hot-button issues regarding the US patent system, including AbbVie’s alleged abuse of it, and his hopes for improvement.

Here are the top 5 biosimilar articles for the week of June 14, 2021.

Product differentiation, global partners, and a large suite of biosimilars in development are ways that Reykjavik, Iceland-based Alvotech expects to stay ahead of the competition.

In part 2 of this panel discussion, 3 experts on India’s biologics industry discuss whether biosimilars can be produced affordably in the country and ways of improving the industry’s image.

Here are the top 5 biosimilar articles for the week of June 7, 2021.

In part 1 of this panel discussion, 3 experts on India’s biologics industry explain what’s missing from current biosimilar regulation and what the country needs to do for its products to compete internationally.

Here are the top 5 biosimilar articles for the week of May 31, 2021.

In part 2 of this interview, Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilar Collective Intelligence Consortium, discusses the potential for interchangeable insulin biosimilars and the challenges of obtaining reliable and optimized real world data.

Here are the top 5 biosimilar articles for the week of May 24, 2021.

In part 1 of this interview, Cate Lockhart, executive director of the Biologics and Biosimilar Collective Intelligence Consortium, details some of her expectations for further growth of the US biosimilar market.

China’s streamlined system for biologics approvals has enabled Shanghai Henlius Biotech to bring biosimilars to market faster and potentially at a lower cost, Ping Cao, vice president of Business Development, explains.

Here are the top 5 biosimilar articles for the week of May 17, 2021.

Here are the top 5 biosimilar articles for the week of May 10, 2021.

Here are the top 5 biosimilar articles for the week of May 3, 2021.

Maria Manley, LLM, a life sciences expert and London-based partner with Sidley Austin, provides a deep-dive look at the complexities of Brexit and how it is likely to challenge the biologics industry.

Here are the top 5 biosimilar articles for the week of April 26, 2021.

Here are the top 5 biosimilar articles for the week of April 19, 2021.

Allen Lising, managing director of Xcenda’s FormularyDecisions, explains how stakeholders are using pre-approval information to make business decisions.

Rebecca Borgert, PharmD, BCOP, and Jim Rebello, PharmD, from Magellan Rx Management talk about how market trends, payer formulary decisions, and international successes are shaping today's biosimilars industry.

Here are the top 5 biosimilar articles for the week of April 12, 2021.

Here are the top 5 biosimilar articles for the week of April 5, 2021.

Richard G. Frank, PhD, and Meaghan Rose Smith discuss a recent white paper on the regulatory and anticompetitive impediments to biosimilar market entry and the hope for biosimilar savings.

Here are the top 5 biosimilar articles for the week of March 29, 2021.

Here are the top 5 biosimilar articles for the week of March 22, 2021.

Kenneth Komorny, PharmD, BCPS, was a co-lead on development of National Comprehensive Cancer Network (NCCN) recommendations for biosimilar management. He explains some of the positions the NCCN has taken.

Here are the top 5 biosimilar articles for the week of March 15, 2021.

State Senator Carla Nelson explains how the pharmaceutical industry is reacting to her bill requiring payers to cover all approved biosimilars and reference products.

Here are the top 5 biosimilar articles for the week of March 8, 2021.